LONDON, March 28, 2014 /PRNewswire/ --
On Wednesday, March 26, 2014, the
NASDAQ Composite ended at 4,173.58, down 1.43%, the Dow Jones
Industrial Average fell 0.60% to 16,268.99, and the S&P 500
closed at 1,852.56, down 0.70%. The losses were broad based as nine
out of 10 sectors ended the session in negative. The S&P 500
Health Care Sector Index finished the day at 672.05, up 0.05%, and
the same has gained 4.63% in the last three months. Investor-Edge
has initiated coverage on the following equities: Array BioPharma
Inc. (NASDAQ: ARRY), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD),
Pharmacyclics Inc. (NASDAQ: PCYC) and Isis Pharmaceuticals Inc.
(NASDAQ: ISIS). Free technical research on ARRY, ACAD, PCYC and
ISIS can be downloaded upon signing up at:
http://www.investor-edge.com/536-register
Array BioPharma Inc.'s stock lost 3.43% on Wednesday, closing at
$4.79, after oscillating between
$4.75 and $5.01. A total of 1.63
million shares were traded, which is above its three months average
volume of 1.35 million. Array BioPharma Inc.'s shares have fallen
by 5.15% in the last one month and 4.39% on YTD basis, while the
same has gained 1.70% in the previous three months. The company's
stock is trading below its 50-day and 200-day moving averages.
Array BioPharma Inc.'s 200-day moving average of $5.44 is above its 50-day moving average of
$5.05. Furthermore, the stock is
trading at a Relative Strength Index (RSI) of 45.70. Sign up today
to read free research on ARRY at:
http://www.investor-edge.com/536-ARRY-27Mar2014.pdf
Shares in ACADIA Pharmaceuticals Inc. witnessed a trading volume
of 2.26 million shares on Wednesday, as compared with a three
months average volume of 1.85 million shares. The stock ended the
day at $22.90, down 3.82% and at an
intraday trading range of $22.80 and
$24.33 during the session. Shares in
ACADIA Pharmaceuticals Inc. have declined 22.95% in the last one
month and 8.36% on YTD basis. The stock is trading above its
200-day moving average. ACADIA Pharmaceuticals Inc.'s 50-day moving
average of $25.59 is above its
200-day moving average of $22.86.
Additionally, the company's shares are trading at an RSI of 38.16.
Sign up today to read free research on ACAD at:
http://www.investor-edge.com/536-ACAD-27Mar2014.pdf
On Wednesday, Pharmacyclics Inc.'s stock declined 1.60%
finishing the session at $108.95. The
stock recorded a trading volume of 1.62 million shares which is
above its three months average volume of $1.22 million. The stock fluctuated between
$108.77 and $113.50 during the
session. Pharmacyclics Inc.'s shares have lost 25.47% in the last
one month, while the same has gained 0.82% in the previous three
months and 3.00% on YTD basis. The stock is trading below its
50-day and 200-day moving averages. Pharmacyclics Inc.'s 50-day
moving average of $133.57 is above
its 200-day moving average of $118.23. Moreover, the shares are trading at a PE
ratio of 136.19 and at an RSI of 25.78. Sign up today to read free
research on PCYC at:
http://www.investor-edge.com/536-PCYC-27Mar2014.pdf
Shares in Isis Pharmaceuticals Inc. recorded a trading volume of
1.75 million shares, as compared with a three months average volume
of 1.71 million shares. The stock ended Wednesday's session at
$42.07, down 3.38%, and at an
intraday trading range of $41.82 and
$45.05. Shares in Isis
Pharmaceuticals Inc. have surged 2.68% in the previous three months
and 5.60% on YTD basis. The stock is trading above its 200-day
moving average. Isis Pharmaceuticals Inc.'s 50-day moving average
of $49.95 is above its 200-day moving
average of $36.73. Further, the
company's shares are trading at an RSI of 36.83. Sign up today to
read free research on ISIS at:
http://www.investor-edge.com/536-ISIS-27Mar2014.pdf
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and
our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
4. If you wish to have your company covered in more detail by
our team, or wish to learn more about our services, please contact
us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at
compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] http://www.investor-edge.com for
consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Investor-edge. An outsourced research services provider represented
by Nidhi Vatsal, CFA, has only reviewed the information provided by
Investor-edge in this article or report according to the Procedures
outlined by Investor-edge. Investor-edge is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Investor-edge
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Investor-edge expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Investor-edge does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
http://www.Investor-Edge.com
SOURCE Investor-Edge